+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of DDY391 in adults with Sjgrens Disease SjD through a Phase 2ab randomized, double-blind, placebo-controlled study. The trial aims to determine the dose-response relationship of DDY391 to support dose selection for Phase 3. The study is conducted across multiple centers and involves participants diagnosed according to specific classification criteria. Participants will be assigned to one of several groups receiving different dose levels of DDY391 or a matching placebo. The study is divided into three parts Parts A, B, and C, with a screening period lasting up to 8 weeks, followed by a 52-week treatment period. At the 24-week visit, participants initially on placebo will be re-randomized to receive DDY391 at dose level 1 or 2. After treatment, there is a 4-week safety follow-up period. During the trial, participants will undergo various assessments including changes from baseline in disease activity scores such as ESSDAI and ESSPRI, and evaluations of symptom severity. Safety will be closely monitored through the recording of adverse events. The total participation duration includes screening, treatment, and safety follow-up, extending over approximately 64 weeks.

Age: 18Years - 100YearsAll GendersPhase 2
25 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
C

Actively Recruiting

Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.

Age: 18Years +All GendersPhase 3
206 locations
C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.

Age: 18Years +All GendersPhase 3
259 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination therapy called BMS-986489 Atigotatug plus Nivolumab with Carboplatin and Etoposide compared to Atezolizumab with Carboplatin and Etoposide. This study focuses on participants with extensive-stage small cell lung cancer to understand which treatment works better as a first-line therapy. It is a Phase 3 clinical trial led by Bristol-Myers Squibb. Participants are randomly assigned to one of two groups one receiving the BMS-986489 combination with Carboplatin and Etoposide, and the other receiving Atezolizumab with Carboplatin and Etoposide. All medications are given at specific doses on designated days. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants undergo regular assessments including imaging scans to measure tumor size, and evaluations of overall survival over up to five years. Researchers also monitor symptoms, response duration, progression-free survival, and any adverse or serious side effects up to 135 days after treatment ends. The study includes detailed safety and efficacy tracking with multiple outcome measures to fully understand the impact of each treatment option.

Age: 18Years +All GendersPhase 3
183 locations
E

Actively Recruiting

Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.

Age: 16Years +All GendersPhase 3
245 locations
C

Actively Recruiting

Researchers are evaluating a new medicine called NNC6019-0001 to see if it can reduce the risk of heart-related death and illness in people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart. This phase 3 study compares NNC6019-0001 to a placebo, with participants continuing their regular heart treatments as advised by their doctors. The study aims to better understand cardiovascular outcomes in this patient group over time. Participants will receive either NNC6019-0001 or a placebo intravenously. Both groups may continue with their usual standard of care treatments as recommended by their healthcare providers. The treatment is given in a parallel design where each participant is randomly assigned to one of the two groups. The study will last up to approximately four years, allowing long-term observation of effects. During the study, participants will be regularly monitored through various assessments including questionnaires about heart health, walking tests, and measurements of heart function and biomarkers. Researchers will track cardiovascular deaths, hospital visits, and heart failure events among other outcomes. Safety and health status will be followed closely throughout the study period to evaluate the impact of the treatment compared to placebo.

Age: 18Years +All GendersPhase 3
299 locations
P

Actively Recruiting

Researchers are evaluating the effect of dalcetrapib on cardiovascular risk in people recently hospitalized for acute coronary syndrome ACS who have a specific genetic profile AA genotype. This phase 3, randomized, double-blind, placebo-controlled study focuses on adults aged 45 years and older, aiming to assess the time to first occurrence of fatal or non-fatal myocardial infarction over an average of 30 months from randomization. The study will continue until around 200 participants experience a primary event, or until stopped at an interim analysis. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily, two 300 mg tablets or matching placebo tablets once daily. Screening includes genetic testing for the AA genotype using a specialized Genotype Assay Test. Enrollment can begin during hospitalization or after discharge, but randomization must occur within 12 weeks of the ACS event. After randomization, follow-up visits will be virtual when possible or in clinic every three months until the study ends. Assessments will continue every three months for participants who stop the study medication early. Participants will undergo medical history review and genetic testing before enrollment. During the study, researchers will monitor cardiovascular events such as heart attacks and strokes through regular assessments every three months. Safety evaluations and collection of study endpoints will continue for the duration of participation, which may last approximately 30 months or until the study stops. This includes ongoing monitoring for adverse effects and overall health status.

Age: 45Years +All GendersPhase 3
231 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating the potential beneficial effects of omega-3 monoglyceride fatty acids on reducing inflammation by studying their impact on peripheral blood mononuclear cells PBMCs. This research focuses on the biological activity of omega-3 fatty acids, which involves selective oxidation by enzymes called lipoxygenases to form substances that help resolve inflammation. The study aims to develop new products by pre-metabolizing omega-3 monoglycerides to enhance this inflammation-resolving activity. The study collects blood samples from participants to isolate PBMCs, which are then cultured with an inflammatory agent called LPS to stimulate cell proliferation. The cells are divided into two groups one treated with the specially processed omega-3 monoglycerides MAG-SPM and the other untreated with MAG-SPM but exposed to LPS. Researchers measure and compare the reduction in cell proliferation between these two groups to assess the activity of the treatment. Participants donate blood samples used for cell isolation. The isolated cells are maintained in laboratory cultures with LPS, and their proliferation is observed with and without MAG-SPM treatment. Researchers count the number of PBMCs over a 12-month period to evaluate the inflammation-resolving effects. This study involves regular laboratory assessments and does not involve direct treatment of participants. Participation duration depends on the blood donation schedule and laboratory testing timeline.

Age: 18Years +All Genders
1 location

1-10 of 22

1